Prostate cancer (PCa) is the second cause of
cancer deaths in men in the USA. When the
cancer recurs, early stages can be controlled with
hormone ablation
therapy to delay the rate of
cancer progression but, over time, the
cancer overcomes its
hormone dependence, becomes highly aggressive and metastasizes. Clinical trials have shown that pomegranate juice (PJ) inhibits PCa progression. We have previously shown that the PJ components
luteolin (L),
ellagic acid (E) and
punicic acid (P) together inhibit growth of
hormone-dependent and -independent PCa cells and inhibit their migration and chemotaxis towards CXCL12, a
chemokine that is important in PCa
metastasis. On the basis of these findings, we hypothesized that L+E+P inhibit PCa
metastasis in vivo. To test this possibility, we used a
severe combined immunodeficiency mouse model in which
luciferase-expressing human PCa cells were injected subcutaneously near the prostate.
Tumor progression was monitored with bioluminescence imaging weekly. We found that L+E+P inhibits PC-3M-luc primary
tumor growth, inhibits the CXCL12/CXCR4 axis for
metastasis and none of the
tumors metastasized. In addition, L+E+P significantly inhibits growth and
metastasis of highly invasive Pten (-/-) ;K-ras (G12D) prostate
tumors. Furthermore, L+E+P inhibits angiogenesis in vivo, prevents human endothelial cell (EC) tube formation in culture and disrupts preformed EC tubes, indicating inhibition of EC adhesion to each other. L+E+P also inhibits the angiogenic factors
interleukin-8 and
vascular endothelial growth factor as well as their induced signaling pathways in ECs. In conclusion, these results show that L+E+P inhibits PCa progression and
metastasis.